{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:26:25Z","timestamp":1794327985270,"version":"4.9.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background &amp; Aims<\/jats:title>\n                    <jats:p>Prolonged washout periods between advanced therapies and investigational drugs are commonly required in inflammatory bowel disease (IBD) randomized controlled trials (RCTs). These requirements restrict patient enrollment and diverge from real-world clinical practice. This study aimed to establish an international expert consensus on washout durations for advanced therapies and conventional immunosuppressants (IS) in IBD clinical trials and to propose methodological recommendations for future study designs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An international panel of 12 IBD clinical trial experts participated in a Delphi consensus process. Agreement of\u2009\u226575% among participants was predefined as consensus.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 12 statements were approved. Consensus was reached to eliminate washout periods for conventional IS (thiopurines, tacrolimus, methotrexate, and mycophenolate mofetil). For golimumab and ozanimod, experts agreed on a 2-week washout period. For other biologics (infliximab, adalimumab, vedolizumab, ustekinumab, and anti\u2013IL-23 agents), most participants favored a 2\u20134-week washout duration and for JAK inhibitors and etrasimod, participants supported a short 2-week washout, though without reaching formal consensus. Experts recommended incorporating washout-based stratification (&amp;lt;4 vs \u22654\u2009weeks) at randomization into future trial designs to evaluate its impact on safety, pharmacokinetics, and efficacy outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This international Delphi consensus highlights the need to adapt current washout practices in IBD RCTs to real-world practice. Experts supported shorter and standardized washout durations\u2014preferably less than 4\u2009weeks\u2014to better align with clinical practice, while maintaining patient safety. Acceptance of these recommendations by regulators could harmonize washout duration criteria, enhance recruitment efficiency, and accelerate patient access to innovative therapies without compromising safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjag060","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T11:40:44Z","timestamp":1776253244000},"source":"Crossref","is-referenced-by-count":0,"title":["Time to rethink washout periods in inflammatory bowel disease clinical trials: an international Delphi consensus"],"prefix":"10.1093","volume":"20","author":[{"given":"Pauline","family":"Wils","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Claude Huriez hospital, University of Lille 2 , Lille,","place":["France"]},{"name":"Inserm, CHU Lille, U1286-INFINITE-Institute for Translational Research in Inflammation, University of Lille , Lille,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1092-0033","authenticated-orcid":false,"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Western University , London, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce E","family":"Sands","sequence":"additional","affiliation":[{"name":"The Dr Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9724-054X","authenticated-orcid":false,"given":"Axel","family":"Dignass","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Agaplesion Markus Hospital, Goethe-University , Frankfurt am Main,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2634-9668","authenticated-orcid":false,"given":"Fernando","family":"Magro","sequence":"additional","affiliation":[{"name":"Centre for Health Technology and Services Research, Health Research Network (CINTESIS@RISE), Faculty of Medicine, University of Porto , Porto,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5647-1723","authenticated-orcid":false,"given":"David T","family":"Rubin","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Center, University of Chicago Medicine , Chicago, IL,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Dotan","sequence":"additional","affiliation":[{"name":"Gray Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv,","place":["Israel"]},{"name":"Division of Gastroenterology, Rabin Medical Center , Petah Tikva,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2088-091X","authenticated-orcid":false,"given":"Walter","family":"Reinisch","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, Division Gastroenterology and Hepatology, Medical University of Vienna , Vienna,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parambir","family":"Dulai","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Northwestern University , Chicago, IL,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Gearry","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Otago , Christchurch,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4698-9948","authenticated-orcid":false,"given":"Christopher","family":"Ma","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Cumming School of Medicine, University of Calgary , Calgary, AB,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Millie","family":"Long","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill , Chapel Hill, NC,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Armuzzi","sequence":"additional","affiliation":[{"name":"IBD Center, Department of Gastroenterology, IRCCS Humanitas Research Hospital , Milan,","place":["Italy"]},{"name":"Department of Biomedical Sciences, Humanitas University , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2073-4234","authenticated-orcid":false,"given":"Taku","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9661-0070","authenticated-orcid":false,"given":"Dan","family":"Turner","sequence":"additional","affiliation":[{"name":"The Juliet Keidan Institute of Pediatric Gastroenterology and Nutrition, The Eisenberg R&D Authority, Shaare Zedek Medical Center, The Hebrew University of Jerusalem , Jerusalem,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1859-7146","authenticated-orcid":false,"given":"Sophie","family":"Vieujean","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Cliniques Universitaires Saint-Luc , Brussels,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3898-7093","authenticated-orcid":false,"given":"Bram","family":"Verstockt","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, UZ Leuven , Leuven,","place":["Belgium"]},{"name":"Department of Chronic Diseases and Metabolism, KU Leuven , Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailsa","family":"Hart","sequence":"additional","affiliation":[{"name":"IBD Unit, St Mark\u2019s Hospital and Imperial College London , London,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7341-1351","authenticated-orcid":false,"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[{"name":"Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2536-6618","authenticated-orcid":false,"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, CHRU Nancy, INSERM NGERE, Universit\u00e9 de Lorraine , Vand\u0153uvre-l\u00e8s-Nancy,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,16]]},"reference":[{"key":"2026111010423497700_jjag060-B1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41572-020-0205-x","article-title":"Ulcerative colitis","volume":"6","author":"Kobayashi","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2026111010423497700_jjag060-B2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41572-020-0156-2","article-title":"Crohn\u2019s disease","volume":"6","author":"Roda","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2026111010423497700_jjag060-B3","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1111\/j.1365-2036.2011.04599.x","article-title":"Review article: remission rates achievable by current therapies for inflammatory bowel disease","volume":"33","author":"Peyrin-Biroulet","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"2026111010423497700_jjag060-B4","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/apt.16781","article-title":"Review article: randomised controlled trials in inflammatory bowel disease-common challenges and potential solutions","volume":"55","author":"Schreiber","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"2026111010423497700_jjag060-B5","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1093\/ecco-jcc\/jjad020","article-title":"Declining enrolment and other challenges in IBD clinical trials: causes and potential solutions","volume":"17","author":"Uzzan","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2026111010423497700_jjag060-B6","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/ueg2.12731","article-title":"Evolution of eligibility criteria in inflammatory bowel disease clinical trials: a clinical trial databank analysis","volume":"13","author":"Outtier","year":"2025","journal-title":"United European Gastroenterol J"},{"key":"2026111010423497700_jjag060-B7","article-title":"Ulcerative colitis: developing drugs for treatment guidance for industry","author":"U.S. Food & Drug Administration"},{"key":"2026111010423497700_jjag060-B8","article-title":"Crohn\u2019s disease: developing drugs for treatment","author":"U.S. Food & Drug Administration"},{"key":"2026111010423497700_jjag060-B9","doi-asserted-by":"publisher","first-page":"4540","DOI":"10.1007\/s10620-023-07837-0","article-title":"Efficacy and safety of dual targeted therapy for partially or non-responsive inflammatory bowel disease: a systematic review of the literature","volume":"68","author":"Berinstein","year":"2023","journal-title":"Dig Dis Sci"},{"key":"2026111010423497700_jjag060-B10","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S2468-1253(22)00427-7","article-title":"Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial","volume":"8","author":"Feagan","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026111010423497700_jjag060-B11","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.cgh.2023.09.011","article-title":"Washout periods in inflammatory bowel disease trials: a systematic literature review and proposed solutions","volume":"22","author":"Wils","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026111010423497700_jjag060-B12","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1053\/j.gastro.2019.08.020","article-title":"Competition for clinical trials in inflammatory bowel diseases","volume":"157","author":"Harris","year":"2019","journal-title":"Gastroenterology"},{"key":"2026111010423497700_jjag060-B13","article-title":"Guideline on the development of new medicinal products for the treatment of Crohn\u2019s disease"},{"key":"2026111010423497700_jjag060-B14","doi-asserted-by":"publisher","first-page":"S341","DOI":"10.1093\/ecco-jcc\/jjab076.439","article-title":"P315 population pharmacokinetics and pharmacodynamics of ozanimod in ulcerative colitis","volume":"15","author":"Tatosian","year":"2021","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"2026111010423497700_jjag060-B15","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1080\/00365521.2019.1666914","article-title":"High anti-TNF alfa drugs trough levels are not associated with the occurrence of adverse events in patients with inflammatory bowel disease","volume":"54","author":"Bodini","year":"2019","journal-title":"Scand J Gastroenterol"},{"key":"2026111010423497700_jjag060-B16","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.cgh.2020.03.018","article-title":"Cumulative Exposure to infliximab, but not trough concentrations, correlates with rate of infection","volume":"19","author":"Landemaine","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026111010423497700_jjag060-B17","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1136\/gutjnl-2022-327025","article-title":"The future of drug development for inflammatory bowel disease: the need to ACT (advanced combination treatment)","volume":"71","author":"Danese","year":"2022","journal-title":"Gut"},{"key":"2026111010423497700_jjag060-B18","doi-asserted-by":"publisher","first-page":"otac002","DOI":"10.1093\/crocol\/otac002","article-title":"Systematic review with meta-analysis: safety and effectiveness of combining biologics and small molecules in inflammatory bowel disease","volume":"4","author":"Alayo","year":"2022","journal-title":"Crohns Colitis 360"},{"key":"2026111010423497700_jjag060-B19","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.cgh.2018.02.024","article-title":"Combining biologics in inflammatory bowel disease and other immune mediated inflammatory disorders","volume":"16","author":"Hirten","year":"2018","journal-title":"clin gastroenterol hepatol"},{"key":"2026111010423497700_jjag060-B20","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1002\/art.20221","article-title":"Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate","volume":"50","author":"Genovese","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2026111010423497700_jjag060-B21","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1136\/annrheumdis-2011-201087","article-title":"Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and\/or TNF inhibitors: a large, open-label study close to clinical practice","volume":"71","author":"Bykerk","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2026111010423497700_jjag060-B22","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1136\/ard.2008.099218","article-title":"The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial","volume":"68","author":"Schiff","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2026111010423497700_jjag060-B23","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1016\/S0140-6736(16)31651-8","article-title":"Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. The","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"2026111010423497700_jjag060-B24","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1136\/annrheumdis-2019-215764","article-title":"Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response","volume":"78","author":"Fleischmann","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2026111010423497700_jjag060-B25","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1136\/annrheumdis-2018-214529","article-title":"Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and\/or study design: phase III data in patients with rheumatoid arthritis","volume":"78","author":"Tanaka","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2026111010423497700_jjag060-B26","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1177\/2050640619841538","article-title":"Impact of first-line infliximab on the pharmacokinetics of second-line vedoli\u00adzumab in inflammatory bowel diseases","volume":"7","author":"Liefferinckx","year":"2019","journal-title":"United European Gastroenterol J"},{"key":"2026111010423497700_jjag060-B27","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1111\/apt.14567","article-title":"Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-tumour necrosis factor","volume":"47","author":"Ben-Horin","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2026111010423497700_jjag060-B28","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.14309\/ajg.0000000000002398","article-title":"Long washout periods between biologics for inflammatory bowel disease clinical trials are unnecessary: a Canadian retrospective cohort study","volume":"118","author":"Vuyyuru","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"2026111010423497700_jjag060-B29","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.cgh.2015.10.029","article-title":"Pharmacokinetic features and presence of antidrug antibodies associate with response to infliximab induction therapy in patients with moderate to severe ulcerative colitis","volume":"14","author":"Brandse","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026111010423497700_jjag060-B30","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/apt.16852","article-title":"Subcutaneous injection of infliximab CT-P13 results in stable drug levels within 14-day treatment cycle in Crohn\u2019s disease","volume":"56","author":"Roblin","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"2026111010423497700_jjag060-B31","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1053\/j.gastro.2021.02.068","article-title":"Randomized controlled trial: subcutaneous vs Intravenous Infliximab CT-P13 maintenance in inflammatory bowel disease","volume":"160","author":"Schreiber","year":"2021","journal-title":"Gastroenterology"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/5\/jjag060\/68343522\/jjag060.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/5\/jjag060\/68343522\/jjag060.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T15:42:40Z","timestamp":1794325360000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjag060\/8687923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,8]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjag060","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,5]]},"article-number":"jjag060"}}